ELV

Business profile & competitive position

Elevance Health Inc. operates in the Healthcare sector, specifically the Medical - Healthcare Plans industry. The company is one of the largest U.S. health insurers, providing integrated medical, pharmacy, and behavioral health services across the care journey. As of December 31, 2025, it served approximately 45.2 million medical members through affiliated health plans. Revenue comes from risk-based premiums, administrative fees, and pharmacy and health services fees, largely through its Carelon businesses.

The company is also an independent licensee of the Blue Cross and Blue Shield Association, operating as the Anthem Blue Cross and/or Blue Cross and Blue Shield licensee in 14 states and territories. It reports through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other.

The financial profile reflects the economics of managed care. The 2.5% net margin is thin, which is typical for an insurer that collects premiums and pays out most of those dollars in medical claims. More telling for competitive moat is the 11.2% ROE: despite a low net margin, the company still converts equity capital into double-digit returns, suggesting meaningful scale, pricing power in government-contract segments, and operational efficiency. The 0.70 beta reinforces a defensive, lower-volatility profile relative to the broader market.

Financial posture

Elevance Health currently carries a market capitalization of $88.4 billion and trades at a P/E ratio of 18.1. The stock is at $407.50, with a 50-day EMA of $394.37 and an RSI of 56.6. That valuation sits in a range that neither screams deep value nor looks stretched relative to large-cap healthcare peers, but it does price in a baseline expectation of stable, mid-single-digit growth and disciplined capital management.

The 2.5% net margin is not a sign of weak competitiveness on its own; it is structural for the industry. The more relevant profitability signal is the 11.2% ROE, which indicates the company is using leverage, scale, and capital-light fee businesses effectively enough to generate a respectable return on book equity. The 0.70 beta signals that the stock has historically moved less dramatically than the overall market, consistent with a payer whose cash flows are tied to recurring premiums and government contracts.

Strategic priorities & outlook

According to the company’s most recent SEC 10-K filing, Elevance Health’s operational focus centers on four priorities:

• Value-based care expansion: Continue promoting payment models that align incentives to deliver care at the right time and setting.
• Portfolio rationalization: Align investments to optimize core businesses, invest in higher-growth opportunities, and accelerate value creation through expanded capabilities and services.
• Technology and service enhancement: Improve interactions with customers, care providers, brokers, agents, and employees through technology that supports distribution, clinical coordination, and administrative efficiency.
• Profitability across segments: Maintain market-competitive value while achieving appropriate profitability across customer segments.

The filing also flags notable operational facts. U.S. government agencies accounted for approximately 32% of total consolidated revenues in 2025, with the majority flowing through the Health Benefits segment. That concentration makes execution in Medicare, Medicaid, and federal employee accounts central to the revenue base. Meanwhile, the Carelon businesses represent the company’s push into adjacent pharmacy and health services revenue streams beyond traditional insurance premiums.

Macro & geopolitical exposure

As a healthcare plan operator, Elevance Health is primarily exposed to domestic policy and regulation rather than currency or commodity cycles. Key macro drivers include Medicare and Medicaid reimbursement rates, changes to the Affordable Care Act, Medicaid expansion or contraction at the state level, and Medicare Advantage rate-setting decisions by federal agencies.

Government revenue concentration is material: roughly 32% of total revenue comes from U.S. government agencies. Shifts in administration, legislation, or regulatory interpretation around prior authorization, medical loss ratios, and network adequacy can directly affect profitability. Because the company owns pharmacy and health services assets through CarelonRx, drug pricing policy and pharmaceutical supply chain dynamics are also relevant. Trade exposure is limited since the business is overwhelmingly U.S.-based, but broader healthcare supply chain constraints and provider labor costs can still influence medical-cost trends.

Recent developments

Recent headlines have centered on institutional positioning and Medicare Advantage turbulence:

• September 7, 2026 — defenseworld.net reported that the California State Teachers Retirement System raised its stake in Elevance Health.
• September 5, 2026 — 247wallst.com published a story noting that insurers have already signaled to Wall Street which Medicare Advantage plans will exit at year-end, while members may not receive notice until October 2.
• September 4, 2026 — defenseworld.net disclosed that Allen Mooney & Barnes Investment Advisors LLC holds roughly $17.94 million in Elevance Health stock.
• August 31, 2026 — defenseworld.net reported that Beaconlight Capital LLC initiated a new position in the company.

The institutional filings suggest continued accumulation by asset managers, but the Medicare Advantage headline is the more operationally relevant item. Because government-sponsored plans represent a meaningful portion of revenue, any contraction or restructuring of Medicare Advantage offerings can move sentiment even when headline earnings appear strong.

Earnings behavior & post-earnings drift

Elevance Health has a solid recent earnings record. Over the last eight reported quarters, it has beaten estimates 6 out of 8 times (75%), with an average earnings surprise of 7.2%. Over the same window, the average 5-day price move after earnings was +2.78%, classified as an “up” drift.

However, the most important pattern for traders and analysts is that a headline beat does not guarantee a continued upward drift. The last four reported quarters were all beats, yet the post-earnings price action was mixed:

• July 15, 2026: Actual EPS of $7.45 vs. estimate $6.21, a 20.0% surprise beat. The stock fell 4.48% the next day and -0.32% over the following five sessions.
• April 22, 2026: Actual EPS of $12.58 vs. estimate $10.82, a 16.3% surprise beat. The stock rose 5.51% the next day and 14.76% over the next five sessions.
• January 28, 2026: Actual EPS of $3.33 vs. estimate $3.10, a 7.4% surprise beat. The stock gained 1.5% the next day but slipped -0.37% over the next five sessions.
• October 21, 2025: Actual EPS of $6.03 vs. estimate $4.93, a 22.3% surprise beat. The stock fell 1.3% the next day and -2.96% over the next five sessions.

This disconnect between EPS beats and post-earning price direction suggests the market is reacting to factors beyond the headline number: forward guidance, medical-cost trends, Medicare Advantage rate commentary, Carelon segment margins, and capital-deployment plans. Next up, Elevance Health is scheduled to report on October 21, 2026, before the market open, with a consensus EPS estimate of $4.66.

For a deeper dive into how sell-side and institutional models are weighing these earnings patterns, strategic priorities, and macro exposures, review the full institutional verdict on the ticker page.